A detailed history of Mercer Global Advisors Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 38,721 shares of AKBA stock, worth $69,310. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,721
Previous 31,221 24.02%
Holding current value
$69,310
Previous $31,000 64.52%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.94 - $1.55 $7,050 - $11,625
7,500 Added 24.02%
38,721 $51,000
Q2 2024

Aug 12, 2024

BUY
$0.86 - $1.63 $7,771 - $14,730
9,037 Added 40.74%
31,221 $31,000
Q1 2024

May 15, 2024

BUY
$1.27 - $2.24 $3,172 - $5,595
2,498 Added 12.69%
22,184 $41,000
Q4 2023

Feb 14, 2024

SELL
$0.8 - $1.28 $219 - $350
-274 Reduced 1.37%
19,686 $24,000
Q2 2023

Aug 14, 2023

BUY
$0.51 - $1.43 $10,179 - $28,542
19,960 New
19,960 $18,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $329M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.